Company: PSTV
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013256
Chunk: 32

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 32
---
 effective upon the filing of the Certificate of Amendment or such later time as specified in the filing with the Secretary of State of Delaware. The timing of the filing of the Certificate of Amendment will be determined by the Board based on its evaluation as to when such action will be the most advantageous to the Company and our stockholders.

**Interests of Officers and Directors in this Proposal

Our officers and directors do not have any substantial interest, direct or indirect, in this proposal.

Reservation of Right to Abandon Amendment to Increase in Authorized Shares of Common Stock**

The Board reserves the right to abandon the amendment of the Certificate of Incorporation to increase the number of authorized shares of our Common Stock at any time before the filing with the Secretary of State of Delaware of the Certificate of Amendment, notwithstanding stockholder approval for the amendment. For example, if the Reverse Stock Split is implemented, the Board may choose to abandon the amendment, since the Reverse Stock Split would effectively increase the number of authorized shares available for future issuance.

#### Vote required
Approval of Proposal No. 3 requires the affirmative vote of a majority of the outstanding shares of Common Stock entitled to vote on this proposal. Abstentions will have the effect of a vote “AGAINST” this proposal.

#### Board Recommendation
**OUR BOARD UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THIS PROPOSAL NO. 3 TO AMEND THE CERTIFICATE OF INCORPORATION TO INCREASE THE AUTHORIZED SHARES OF COMMON STOCK FROM 100,000,000 SHARES TO 2,000,000,000 SHARES.**

<div align='center'>19</div>

#### TABLE OF CONTENTS
<div align='center'>**PROPOSAL 4: APPROVAL OF THE EXTENSION OF THE TERM OF THE SERIES B WARRANTS**</div>

### Background and Overview
On May 9, 2024, the Company issued in a private placement (the “May Offering”) to certain accredited investors, including certain of our executive officers and directors, among other securities, Series B common stock purchase warrants (the “May 2024 Warrants”) to purchase shares of Common Stock. On February 13, 2025, the Company consummated the previously announced transaction pursuant to that certain securities purchase and exchange agreement (the “SPEA”) with investors in the May Offering other than those of our executive officers and directors who had participated in the May Offering. As a requirement to enter into the SPEA, the Outside Investors required the